Nueclear Web Banner
Home About us Editorial board Ahead of print Current issue Search Archives Submit article Instructions Subscribe Contacts Login 
REVIEW ARTICLE
Year : 2017  |  Volume : 13  |  Issue : 1  |  Page : 9-15

Genomic aberrations in non- small cell lung cancer and their impact on treatment outcome


1 Department of Medical Oncology, Faculty of Medicine, Zagazig University, Zagazig, Egypt; Oncology Center, King Abdullah Medical City-Holy Capital, Makkah, Saudi Arabia
2 Oncology Center, King Abdullah Medical City-Holy Capital, Makkah, Saudi Arabia
3 Batterjee Medical College, Jeddah, Saudi Arabia
4 Faculty of Medicine, Umm Al-Qura University, Makkah, Saudi Arabia

Correspondence Address:
Amrallah A Mohammed
Muzdallifa Streat, P.O. Box 57657, 21995 Mecca, Saudi Arabia

Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0973-1482.180605

Rights and Permissions

The therapeutic options of nonsmall cell lung cancer (NSCLC) therapy has been changed since the first discovery of activating epidermal growth factor receptor (EGFR) mutations and the development of specific EGFR tyrosine kinase inhibitors, which resulted in the evolution of “personalized medicine.” There are a considerable number of genomic aberrations in NSCLC serving as potential predictive biomarkers and drug targets and still more. We summarized the molecular pathways, potential targets, and possible impact on disease outcome in NSCLC.


[FULL TEXT] [PDF]*
Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)
 

 Article Access Statistics
    Viewed1391    
    Printed87    
    Emailed0    
    PDF Downloaded104    
    Comments [Add]    

Recommend this journal